MaxCyte Regulatory News (MXCT)

MaxCyte Announces Presentation at ICLE 2019

Gaithersburg, Maryland - 9 September 2019 - MaxCyte (LSE: MXCT, MXCS), the global cell-based therapies and life sciences company, announces today that Director of Field Applications Scientists Christopher Mann, PhD, will present on "Advancing Adoptive Cellular Therapies Using Non-viral-based Engineering" at the 2nd International Conference on Lymphocyte Engineering (ICLE 2019)on Saturday 14 September at 9:50 a.m. BST.

The conference takes place 13-15 September 2019 at Novotel London West Hotel, London, United Kingdom. For more information, please visit: https://lymphocyte.kenes.com/

About MaxCyte

MaxCyte is a clinical-stage global cell-based therapies and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. MaxCyte is developing novel CARMA therapies for its own pipeline, with its first drug candidate in a Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. In addition, through its life sciences business, MaxCyte leverages its Flow Electroporation Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its flow electroporation instruments worldwide, including with all of the top ten global biopharmaceutical companies. The Company now has more than 80 partnered programme licenses in cell therapy with more than 45 licensed for clinical use, including four announced commercial licenses with aggregate potential milestones of more than $250m. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com.

For further information, please contact: